Celecoxib Treated Patients:
- Diagnosis of FAP based on the expression of the FAP phenotype.
- Celecoxib treatment prescribed outside of a clinical trial setting with expected
duration of celecoxib treatment of at least six months.
Historical/Concurrent Control Patients:
- Diagnosis of FAP based on the expression of the FAP phenotype.
- Be greater than or equal to 12 years old at the time of study enrollment.
- Have an endoscopically assessable colonic, rectal, ileal pouch and/or gastroduodenal
segment.
- For the group of post-surgical patients, IRA or IPAA performed from 1985 onward (in
order to assure standardized surgical techniques and post-surgical management).
Patients whose primary colorectal surgery was performed prior to 1985 will not be
eligible to serve as historical controls.
Celecoxib Treated Patients:
- Have received a pharmacological treatment (other than celecoxib) within the last 3
months for their FAP disease including treatment of any extracolonic manifestation of
FAP.
- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months,
other than celecoxib, for any reason.
Historical/Concurrent Control Patients:
- Have pharmacological treatment recorded for their FAP disease at the defined index
date.
- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months
for any reason.